0.4882
2.91%
0.0138
Handel nachbörslich:
.50
0.0118
+2.42%
Schlusskurs vom Vortag:
$0.4744
Offen:
$0.4745
24-Stunden-Volumen:
351.55K
Relative Volume:
0.62
Marktkapitalisierung:
$19.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.83M
KGV:
-0.5677
EPS:
-0.86
Netto-Cashflow:
$-20.87M
1W Leistung:
-14.35%
1M Leistung:
+12.23%
6M Leistung:
-74.70%
1J Leistung:
-53.94%
Cognition Therapeutics Inc Stock (CGTX) Company Profile
Firmenname
Cognition Therapeutics Inc
Sektor
Branche
Telefon
412-481-2210
Adresse
2403 SIDNEY STREET, PITTSBURGH
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-11-03 | Eingeleitet | B. Riley Securities | Buy |
2021-11-03 | Eingeleitet | Oppenheimer | Outperform |
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
Cognition Therapeutics stock rated Buy, target held amid CT1812 data By Investing.com - Investing.com UK
November’s Small-Cap Treasures: 3 Stocks Poised for Growth - MarketBeat
Cognition Therapeutics (NASDAQ:CGTX) Earns Buy Rating from Chardan Capital - Defense World
Cognition Therapeutics Presents Poster of Participant - GlobeNewswire
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with - The Bakersfield Californian
Cognition Therapeutics reports potential Alzheimer's treatment breakthrough By Investing.com - Investing.com South Africa
Cognition Therapeutics reports potential Alzheimer's treatment breakthrough - Investing.com
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - GlobeNewswire
Cognition Therapeutics (CGTX) Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD - StreetInsider.com
Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Dementia Associated With Alzheimer's Disease Pipeline - openPR
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of - GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate ... - The Bakersfield Californian
Cognition Therapeutics Releases New Episode of - GlobeNewswire
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies At The Horizon Expected To Transform The Treatment Paradigm, Assesses D... - MENAFN.COM
Tau Inhibitors Clinical Trial Pipeline Analysis - GlobeNewswire
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - India Shorts
Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ... By GuruFocus - Investing.com Canada
Cognition Therapeutics stock hits 52-week low at $0.4 - Investing.com
VEGFR-2 Antagonists Clinical Trial Pipeline Insights Featuring 25+ Companies | DelveInsight - GlobeNewswire
Cognition Therapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com South Africa
Alzheimer's Disease Clinical Trials 2024: EMA, PDMA, FDA - openPR
Cognition Therapeutics Inc (CGTX) presents a great opportunity, but the stock is slightly undervalued - US Post News
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference - ForexTV.com
Cognition Therapeutics Inc (CGTX)’s Day in Review: Closing at 0.47, Up by 11.36 - The Dwinnex
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved - The Bakersfield Californian
Cognition Therapeutics Supports Lewy Body Dementia - GlobeNewswire
Cognition Therapeutics Highlights CT1812 Potential in CNS Disorders - TipRanks
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Sees Large Decrease in Short Interest - Defense World
Cognition Therapeutics Inc (CGTX) Stock: A Year of Decreases and Increases - The InvestChronicle
Trading Day Review: Cognition Therapeutics Inc (CGTX) Loses Momentum, Closing at 0.41 - The Dwinnex
Conduit Pharmaceuticals Inc (CDT) expanding its growth trajectory ahead - SETE News
Capricor Therapeutics rockets on plan to file BLA for full approval of deramiocel - The Pharma Letter
Point72 DIFC Ltd Acquires New Holdings in The Carlyle Group Inc. (NASDAQ:CG) - Defense World
Stock Performance Spotlight: Comtech Telecommunications Corp. (CMTL) Ends the Day at 4.46, Down by -1.11 - The Dwinnex
Pacer Advisors Inc. Boosts Stake in Cognizant Technology Solutions Co. (NASDAQ:CTSH) - Defense World
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
9,460 Shares in Churchill Downs Incorporated (NASDAQ:CHDN) Acquired by Intech Investment Management LLC - Defense World
Catalent (NYSE:CTLT) Lowered to Hold at Baird R W - Defense World
Cognizant Technology Solutions Co. (NASDAQ:CTSH) Shares Bought by Blair William & Co. IL - Defense World
Chord Energy Co. (NASDAQ:CHRD) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Nippon Shinyaku buys $15 million of Capricor Therapeutics stock - Investing.com
Capricor Therapeutics price target raised to $25 from $12 at Maxim - TipRanks
Conduit Pharmaceuticals Inc [CDT] Insider Activity: An Update for Investors - Knox Daily
Capricor Therapeutics Inc. (NASDAQ:CAPR) Stock Rockets 53% On Heavy Volume: How To Trade Now? - DRP Journal
HC Wainwright Reaffirms "Buy" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Blair William & Co. IL Sells 507 Shares of The Carlyle Group Inc. (NASDAQ:CG) - Defense World
Prepare Yourself for Liftoff: Comtech Telecommunications Corp. (CMTL) - SETE News
Capricor stock surges on pipeline update (NASDAQ:CAPR) - Seeking Alpha
Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):